Key facts
- This page summarizes Mark Auerbach's Form 4 filing for PARDES BIOSCIENCES, INC..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Jun 2023, 16:04.
Mark Auerbach - 01 Jun 2023 Form 4 Insider Report for PARDES BIOSCIENCES, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2023, 16:04:15 UTC
- Prior SEC filing
- 10 Jun 2022
- Next SEC filing
- 31 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Lacy, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Auerbach filed Form 4 for PARDES BIOSCIENCES, INC. on 02 Jun 2023.
Change
- Previous filing in this sequence was filed on 10 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PRDS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +37,500
- Change %
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 01 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,500
- Exercise price
- $1.87
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders.